Literature DB >> 24667850

Induction of the calcineurin variant CnAβ1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization.

Marina M López-Olañeta1, María Villalba1, Jesús M Gómez-Salinero1, Luis J Jiménez-Borreguero2, Ross Breckenridge3, Paula Ortiz-Sánchez1, Pablo García-Pavía4, Borja Ibáñez5, Enrique Lara-Pezzi6.   

Abstract

AIMS: Ventricular remodelling following myocardial infarction progressively leads to loss of contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the calcineurin splicing variant, CnAβ1, has beneficial effects on the infarcted heart. However, whether this variant limits necrosis or improves remodelling is still unknown, precluding translation to the clinical arena. Here, we explored the effects and therapeutic potential of CnAβ1 overexpression post-infarction. METHODS AND
RESULTS: Double transgenic mice with inducible cardiomyocyte-specific overexpression of CnAβ1 underwent left coronary artery ligation followed by reperfusion. Echocardiographic analysis showed depressed cardiac function in all infarcted mice 3 days post-infarction. Induction of CnAβ1 overexpression 1 week after infarction improved function and reduced ventricular dilatation. CnAβ1-overexpressing mice showed shorter, thicker scars, and reduced infarct expansion, accompanied by reduced myocardial remodelling. CnAβ1 induced vascular endothelial growth factor (VEGF) expression in cardiomyocytes, which resulted in increased infarct vascularization. This paracrine angiogenic effect of CnAβ1 was mediated by activation of the Akt/mammalian target of rapamycin pathway and VEGF.
CONCLUSIONS: Our results indicate that CnAβ1 exerts beneficial effects on the infarcted heart by promoting infarct vascularization and preventing infarct expansion. These findings emphasize the translational potential of CnAβ1 for gene-based therapies. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Akt; Calcineurin; Cardiac remodelling; CnAβ1; Myocardial infarction

Mesh:

Substances:

Year:  2014        PMID: 24667850     DOI: 10.1093/cvr/cvu068

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  16 in total

Review 1.  Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine.

Authors:  Emanuele Barbato; Paul J Barton; Jozef Bartunek; Sally Huber; Borja Ibanez; Daniel P Judge; Enrique Lara-Pezzi; Craig M Stolen; Angela Taylor; Jennifer L Hall
Journal:  J Cardiovasc Transl Res       Date:  2015-10-09       Impact factor: 4.132

Review 2.  Calcineurin signaling in the heart: The importance of time and place.

Authors:  Valentina Parra; Beverly A Rothermel
Journal:  J Mol Cell Cardiol       Date:  2016-12-20       Impact factor: 5.000

Review 3.  Alternative splicing isoforms in health and disease.

Authors:  Hyoung Kyu Kim; Michael Huy Cuong Pham; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2018-03-13       Impact factor: 3.657

4.  The unique C terminus of the calcineurin isoform CNAβ1 confers non-canonical regulation of enzyme activity by Ca2+ and calmodulin.

Authors:  Rachel Bond; Nina Ly; Martha S Cyert
Journal:  J Biol Chem       Date:  2017-08-25       Impact factor: 5.157

5.  Guidelines for translational research in heart failure.

Authors:  Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher
Journal:  J Cardiovasc Transl Res       Date:  2015-01-21       Impact factor: 4.132

Review 6.  Calcineurin in the heart: New horizons for an old friend.

Authors:  Malay Chaklader; Beverly A Rothermel
Journal:  Cell Signal       Date:  2021-08-25       Impact factor: 4.315

7.  Bmi1-Progenitor Cell Ablation Impairs the Angiogenic Response to Myocardial Infarction.

Authors:  Diego Herrero; Susana Cañón; Beatriz Pelacho; María Salvador-Bernáldez; Susana Aguilar; Cristina Pogontke; Rosa María Carmona; Jesús María Salvador; Jose María Perez-Pomares; Ophir David Klein; Felipe Prósper; Luis Jesús Jimenez-Borreguero; Antonio Bernad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

8.  Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy.

Authors:  Ke-Qiong Deng; Aibing Wang; Yan-Xiao Ji; Xiao-Jing Zhang; Jing Fang; Yan Zhang; Peng Zhang; Xi Jiang; Lu Gao; Xue-Yong Zhu; Yichao Zhao; Lingchen Gao; Qinglin Yang; Xue-Hai Zhu; Xiang Wei; Jun Pu; Hongliang Li
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

9.  Alternative Splicing of NOX4 in the Failing Human Heart.

Authors:  Zoltán V Varga; Márton Pipicz; Júlia A Baán; Tamás Baranyai; Gábor Koncsos; Przemyslaw Leszek; Mariusz Kuśmierczyk; Fátima Sánchez-Cabo; Pablo García-Pavía; Gábor J Brenner; Zoltán Giricz; Tamás Csont; Luca Mendler; Enrique Lara-Pezzi; Pál Pacher; Péter Ferdinandy
Journal:  Front Physiol       Date:  2017-11-22       Impact factor: 4.566

10.  Intravenous delivery of adeno-associated virus 9-encoded IGF-1Ea propeptide improves post-infarct cardiac remodelling.

Authors:  Enrique Gallego-Colon; Maria Villalba; Joanne Tonkin; Francisco Cruz; Juan Antonio Bernal; Luis J Jimenez-Borregureo; Michael D Schneider; Enrique Lara-Pezzi; Nadia Rosenthal
Journal:  NPJ Regen Med       Date:  2016-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.